ADAG stock forecast, quote, news & analysis
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies... Show more
Why Adagene Inc. (ADAG) Is Up +48% in the Last 30 Days
Key Takeaways
- ADAG stock surged +48% over the past 30 days, driven by positive clinical updates on muzastotug (ADG126) and anticipation ahead of AACR presentations.
- Over the past quarter, shares rose +140%, fueled by FDA Fast Track designation, partnerships, and strong Phase 1b/2 data in microsatellite stable (MSS) colorectal cancer.
- Key catalysts include muzastotug's promising safety at higher doses, Sanofi investment, and ongoing Phase 2 trial enrollment ahead of schedule.
- Biotech sector sentiment and institutional buying supported the upward momentum amid volatile trading.
- Cash runway extended to early 2028, bolstering confidence in pipeline advancement.
Adagene Inc. (ADAG) Company Overview and Market Position
Adagene Inc. (ADAG) is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. Headquartered in Suzhou, China, the firm leverages its proprietary Dynamic Precision Library (DPL) platform, incorporating NEObody™, SAFEbody®, and POWERbody™ technologies to engineer antibodies with enhanced specificity and safety profiles. Adagene's pipeline targets challenging cancers through masked antibodies that activate preferentially in the tumor microenvironment, reducing off-tumor toxicity.
In the competitive biotechnology landscape, Adagene differentiates itself with its SAFEbody technology, enabling higher dosing of checkpoint inhibitors like anti-CTLA-4 without the severe immune-related adverse events (irAEs) common in first-generation therapies. This positions the company favorably in immuno-oncology, particularly for hard-to-treat solid tumors, explaining recent stock price strength tied to clinical milestones validating its platforms.
Adagene Inc. (ADAG) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ADAG stock climbed +48%, from approximately $2.97 to $4.41, amid heightened volatility with daily swings exceeding 10% on high volume. The move was trend-driven, accelerating in late March on clinical news, breaking above key resistance levels like the 50-day moving average.
For the past quarter, shares rocketed +140%, from around $1.84 to $4.41, reflecting a steady uptrend punctuated by spikes on catalysts. Trading volume surged on key days, such as mid-March (+2M shares), underscoring investor enthusiasm in this biotech name's recovery from 52-week lows near $1.30.
What Drove ADAG Stock Price in the Last 30 Days
The 30-day rally stemmed from escalating buzz around muzastotug (ADG126), Adagene's lead anti-CTLA-4 SAFEbody. Highlights included announcements of two AACR Annual Meeting presentations on ADG126's tumor microenvironment targeting and combination potential with pembrolizumab (Keytruda), sparking optimism for upcoming data readouts. Conference spotlights at Leerink and Oppenheimer further teased Phase 2 progress in late-line MSS colorectal cancer (CRC), driving sentiment shifts.
Recent financial results revealed a $74.5M cash position, extending runway to 2028, while YTD revenue jumped on licensing deals. Biotech market trends favored small-cap innovators amid broader sector rotation, amplifying ADAG's gains on elevated volume.
What Drove ADAG Stock Performance Over the Last Quarter
The quarter's +140% surge built on sustained clinical and regulatory wins. Pivotal was the FDA Fast Track designation in December 2025 for muzastotug plus Keytruda in MSS metastatic CRC without liver metastases, triggering immediate 13-16% premarket pops on evidence of deep responses and favorable safety at 10-20x higher doses versus legacy CTLA-4 agents.
January's business update reaffirmed Q1 2026 data milestones, ASCO 2025 safety data, and Sanofi’s up to $25M investment for Phase 2 funding. Institutional accumulation, including new stakes by Exome Asset Management, reinforced the trend. Macro biotech tailwinds, like interest in next-gen immunotherapies, compounded company-specific momentum amid low-float dynamics.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from among hundreds that analyze thousands of tickers across various markets. These curated bots employ diverse strategies, including trend-following, mean reversion, and momentum plays, with performance metrics like win rate, average return, and Sharpe ratio prominently displayed. Optimized for short-term, swing, or long-term horizons, they adapt to volatility in stocks like ADAG. Investors can explore real-time rankings, backtests, and live signals to enhance their stock analysis and market trends monitoring. Check out the Trending AI Robots page to see how these tools could complement your trading.
ADAG Stock Forecast Drivers: What Investors Should Watch Next
Key monitors include Q1 2026 data from the Phase 1b/2 muzastotug + pembrolizumab trial in 3L+ MSS CRC, AACR posters, and randomized Phase 2 enrollment/readouts (ORR primary endpoint) slated for 1H 2027. Upcoming earnings, full Phase 2 results, and potential Phase 3 initiation loom large.
Industry trends in immuno-oncology, SAFEbody adoption, macro biotech funding, and regulatory feedback (e.g., End-of-Phase 2) will shape sentiment. Risks encompass trial delays, binary data outcomes, dilution from ATM offerings; catalysts like new partnerships or label expansions could propel further.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ADAG sees MACD Histogram just turned negative
ADAG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on June 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADAG as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ADAG moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADAG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ADAG broke above its upper Bollinger Band on May 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ADAG entered a downward trend on May 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 74 cases where ADAG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADAG advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ADAG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.671) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). ADAG has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (21.978) is also within normal values, averaging (357.550).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADAG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology